Treatment
Lenacapavir clinical trials
We’re tracking 12 recruiting studies that include Lenacapavir, each written for real people, not researchers, below.
Recruiting studies
- NCT07473778Recruiting
Study of Lenacapavir for HIV Prevention
This trial tests a new medication, lenacapavir, to see how well it works for preventing HIV. It is for people who want or need PrEP (a medicine to prevent HIV) and are interested in learning about different options.
Birmingham, AlabamaAges 18 years+ - NCT07682961RecruitingPhase 3
Study of new HIV injection vs. standard injectables
This phase 3 trial tests a new long-acting, injectable two-drug combination (lenacapavir + teropavimab + zinlirvimab) vs. another injectable combo (cabotegravir + rilpivirine) for people whose HIV is already well-controlled on daily oral meds. It aims to see if the new combo can keep the virus under control with fewer injections.
San Francisco, CaliforniaAges 18 years+ - NCT07708727RecruitingPhase 2/Phase 3
Injectable HIV treatment vs daily pill for new patients
This trial tests a new injectable HIV treatment (GS-3242 plus lenacapavir) compared to the daily pill Biktarvy for people just starting HIV therapy. If you qualify, you would receive shots every few weeks instead of taking a daily pill.
Ft. Pierce, FloridaAges 18 years+ - NCT07645287RecruitingPhase 2
New HIV Combination Therapy for People on Biktarvy
This study tests a new HIV medication (GS-3242) combined with lenacapavir against your current Biktarvy regimen. Both are all-oral treatments for people whose HIV is well-controlled.
Beverly Hills, CaliforniaAges 18 years+ - NCT06749054RecruitingPhase 2
Long-acting HIV treatment for teens and children with drug resistance
This trial tests a long-acting injection called lenacapavir for children and teens with HIV who have tried other treatments and still have detectable virus. It may be an option if current medicines aren't working well enough.
Atlanta, GeorgiaAges Up to 17 years - NCT07683000RecruitingPhase 3
Study of three HIV drugs for adults with controlled HIV
This trial tests a new combination of three medications, lenacapavir, teropavimab, and zinlirvimab, for people with HIV who currently have undetectable virus levels on a stable oral treatment. The goal is to see if these drugs can keep the virus suppressed, possibly allowing a simpler treatment plan.
Berkeley, MichiganAges 18 years+ - NCT07497594Recruiting
Twice-yearly shots to prevent HIV
This trial tests a new HIV prevention medicine called lenacapavir, given as a shot every six months. It's for young people at risk of HIV who haven't used PrEP before or have had gaps in their PrEP use.
Manaus, AmazonasAges 16–30 - NCT07467018Recruiting
Mobile van study of a long-acting HIV prevention shot
This study tests if giving a long-acting HIV prevention shot (lenacapavir) from a mobile medical van can reach people at risk for HIV in Los Angeles County. You may be able to join if you are HIV negative, at risk for HIV, and are willing to try a shot instead of a daily pill.
Santa Monica, CaliforniaAges 18 years+ - NCT06799338Recruiting
Study of lenacapavir for HIV treatment in France
This study looks at how well lenacapavir works when added to a personalized HIV treatment plan. If you have HIV and received lenacapavir as your first dose between June 2023 and June 2024, this research may help understand its real-world effects.
Paris, Île-de-France RegionAges 18 years+ - NCT06819176RecruitingPhase 1
Adding lenacapavir to disrupt HIV reservoirs in suppressed people
This trial tests whether adding a new long-acting drug, lenacapavir, to your current HIV treatment can reduce the hidden HIV that remains in your body even when standard treatment keeps the virus undetectable. The goal is to see if this can lead to better control of HIV over time.
Bethesda, MarylandAges 18–75 - NCT07518914Recruiting
Learning About New HIV Prevention for Young Women
This study helps researchers understand how to share accurate information about lenacapavir, a newer HIV prevention method, with young women in South Africa. You'll participate in educational activities and share your thoughts to help improve how this information reaches people who need it.
JohannesburgAges 18–29 - NCT07218211RecruitingPhase 4
Injectable PrEP study for Latine transgender women and gay men
This study offers a long-acting injectable form of PrEP (lenacapavir) to prevent HIV in Latine transgender women and gay men in the South. It aims to make HIV prevention easier by providing a shot instead of a daily pill.
Durham, North CarolinaAges 18 years+
What Lenacapavir is being studied for
Conditions with recruiting Lenacapavir studies.
Common questions
- Are there clinical trials studying Lenacapavir?
- Yes. Clin2 currently lists 12 recruiting studies that include Lenacapavir, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Lenacapavir trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Lenacapavir an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Lenacapavir or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.